Invst LLC Invests $156,000 in Evaxion Biotech A/S (NASDAQ:EVAX)

Invst LLC bought a new position in Evaxion Biotech A/S (NASDAQ:EVAX) in the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm bought 54,000 shares of the company’s stock, valued at approximately $156,000. Invst LLC owned 1.00% of Evaxion Biotech A/S as of its most recent SEC filing.

Separately, Armistice Capital LLC boosted its position in shares of Evaxion Biotech A/S by 6.8% in the second quarter. Armistice Capital LLC now owns 392,000 shares of the company’s stock worth $1,137,000 after buying an additional 25,000 shares during the period. Hedge funds and other institutional investors own 11.04% of the company’s stock.

Evaxion Biotech A/S Price Performance

Shares of NASDAQ:EVAX opened at $3.11 on Tuesday. The company has a current ratio of 2.80, a quick ratio of 2.80 and a debt-to-equity ratio of 7.99. Evaxion Biotech A/S has a 1 year low of $2.26 and a 1 year high of $13.61. The business has a fifty day simple moving average of $3.01 and a 200 day simple moving average of $3.31. The firm has a market cap of $16.83 million, a price-to-earnings ratio of -0.72 and a beta of -0.27.

Evaxion Biotech A/S (NASDAQ:EVAX) last announced its quarterly earnings data on Wednesday, August 14th. The company reported ($0.12) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.02 by ($0.14). The company had revenue of $0.15 million during the quarter, compared to analyst estimates of $0.10 million. During the same period last year, the company posted ($2.10) EPS. As a group, sell-side analysts predict that Evaxion Biotech A/S will post -0.24 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Separately, HC Wainwright reaffirmed a “buy” rating and issued a $14.00 target price on shares of Evaxion Biotech A/S in a research report on Thursday, September 26th.

Evaxion Biotech A/S Company Profile

Evaxion Biotech A/S, a clinical-stage biotech company, engages in developing artificial intelligence-powered immunotherapies. The company develops EVX-01, which is in phase 2 global multi-center clinical trial for the treatment of metastatic melanoma; EVX-02, a DNA-based vaccine that is in Phase 1/2a trial designed to induce a therapeutic immune response in the adjuvant setting in patients with resected melanoma; and EVX-03, DNA-based cancer vaccine for the treatment of various cancers.